期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1111/bjh.19148
关键词
BCMA; bispecific antibody; CAR-T; CAR T-Cells; GPRC5D; multiple myeloma
类别
This retrospective single-centre study investigated the outcomes of relapsed multiple myeloma patients who failed various treatments, and found that patients who failed anti-BCMA therapy had poor prognosis, highlighting the unmet medical need in this population.
Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody and therapies targeting B-cell maturation antigen (BCMA) (Quad-class exposed [QCE]). In this retrospective single-centre study, we determined progression-free survival (PFS) and overall survival (OS) from anti-BCMA failure in 45 QCE patients. Seven (16%) patients received antibody-drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR-T cell. Thirty patients (67%) received >= 1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4-12.5) and OS 6.3 months (95% CI = 3.9-14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据